Protocol for pathologic examination of bladder cancer according to the updates of the 5th edition of the WHO classification (2022): biopsy and transurethral resection specimens
DOI:
https://doi.org/10.14739/2310-1237.2024.3.313797Keywords:
bladder cancer, urothelial carcinoma, standardized pathologic examination protocol, stage, grade, histologic subtype, biopsy, TURBTAbstract
Bladder cancer (BC) is the ninth most common malignancy in the world, and BC morbidity and mortality prevail in industrialized countries and, in particular, in Central and Eastern Europe compared to global rates. The availability of a standardised structured protocol for pathological examination of primary biopsy and transurethral resection (TURBT) samples of the bladder, including the latest updates to the 5th edition of the WHO classification of urinary and male genital tumours (2022), will significantly improve the quality of diagnosis and influence the choice of the optimal trajectory for further treatment.
The aim of the study is to highlight the key updates of the latest WHO classification of BC (2022), to study the standards and protocols for pathological examination of BC specimens used in world practice, as well as to develop a Ukrainian version of the protocol for pathological examination of BC, which will include clinically relevant aspects.
Materials and methods. Analysis of literature in PubMed and Web of Science databases using the keywords: bladder cancer, pathology report, grade, stage, histological subtype, biopsy, TURBT, WHO 2022.
Results. The review highlights the latest updates of the WHO classification of BC cancer and proposes standardized pathology protocol for specimens after primary biopsy/TURBT, developed by adapting existing international recommendations of the College of American Pathologists and the International Collaboration on Cancer Reporting.
Conclusions. Adaptation and standardization of the pathological examination protocol for BC will significantly improve the quality of diagnosis, improve the choice of appropriate therapy and may pave the way for the future development of standardized pathological examination protocols for tumors of other localizations for their widespread use by pathologists in Ukraine.
References
Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F. Global Cancer Observatory: Cancer Today [Internet].. Lyon, France: International Agency for Research on Cancer; 2024 [cited 2024 Jul 27]. Available from: https://gco.iarc.who.int/today
Fedorenko ZP, Hulak LO, Mykhailovych YY, Horokh YL, Ryzhov AU, Sumkina OV, et al. [Cancer in Ukraine, 2022-2023. Morbidity, mortality, performance indicators of the oncology service] [Internet]. Bulletin of the National Cancer Registry of Ukraine. 2024;22. Ukrainian. Available from: http://ncru.inf.ua/publications/BULL_25/index.htm#rubriki
Gontero P, Birtle A, Compérat E, Dominguez Escrig JL, Liedberg F, Mariappan P, et al. EAU Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and CIS) [Internet]. Cloudfront.net. [cited 2024 Jun 27]. Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Non-muscle-Invasive-Bladder-Cancer-2024.pdf
Witjes JA, Bruins HM, Carrión A, Cathomas R, Compérat EM, Efstathiou JA, et al. EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer [Internet]. Cloudfront.net. [cited 2024 Jun 27]. Available from: https://d56bochluxqnz.cloudfront.net/documents/full-guideline/EAU-Guidelines-on-Muscle-Invasive-and-Metastatic-Bladder-Cancer-2024.pdf
Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. 2020;77(4):420-33. doi: https://doi.org/10.1016/j.eururo.2019.09.006
Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152-65. doi: https://doi.org/10.1016/j.ccr.2014.01.009
Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer. Cell. 2017;171(3):540-556.e25. doi: https://doi.org/10.1016/j.cell.2017.09.007
Damrauer JS, Hoadley KA, Chism DD, Fan C, Tiganelli CJ, Wobker SE, et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A. 2014;111(8):3110-5. doi: https://doi.org/10.1073/pnas.1318376111
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315-22. doi: https://doi.org/10.1038/nature12965
WHO classification of tumours: urinary and male genital tumours. 5th ed. Vol. 8. Lyon, France: IARC; 2022.
Varma M, Srigley JR, Brimo F, Compérat E, Delahunt B, Koch M, et al. Dataset for the reporting of urinary tract carcinoma-biopsy and transurethral resection specimen: recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol. 2020;33(4):700-12. doi: https://doi.org/10.1038/s41379-019-0403-9
The Royal College of Pathologists. Cancer datasets and tissue pathways [Internet]. Rcpath.org. [cited 2024 Jun 27]. Available from: https://www.rcpath.org/profession/guidelines/cancer-datasets-and-tissue-pathways.html
Cancer Protocol Templates [Internet]. College of American Pathologists. 2017 [cited 2024 Jun 27]. Available from: https://www.cap.org/protocols-and-guidelines/cancer-reporting-tools/cancer-protocol-templates
Royal College of Pathologists of Australia. Cancer protocols [Internet]. Royal College of Pathologists of Australia. Available from: https://www.rcpa.edu.au/Library/Practising-Pathology/Structured-Pathology-Reporting-of-Cancer/Cancer-Protocols-Pre
Grignon D, Brimo F, Comperat E, Delahunt B, Koch M, Lopez-Beltran A, et al. Urinary Tract Carcinoma Histopathology Reporting Guide – Biopsy and Transurethral Resection Specimen. 1st edition. International Collaboration on Cancer Reporting; Sydney, Australia: International Collaboration on Cancer Reporting; 2018.
Grignon D, Brimo F, Comperat E, Delahunt B, Koch M, Lopez-Beltran A, et al. Carcinoma of the Bladder, Histopathology Reporting Guide. 1st edition. Sydney, Australia: International Collaboration on Cancer Reporting; 2018.
College of American Pathologists. Protocol for the Examination of Biopsy and Transurethral Resection of Bladder Tumor (TURBT) Specimens From Patients With Carcinoma of the Urinary Bladder [Internet]. 2023 [cited 2024 Jun 24]. Available from: https://documents.cap.org/protocols/Bladder.Bx.TURBT_4.2.0.0.REL_CAPCP.pdf?_gl=1*19x7b0f*_ga*NTE3OTU2MjcyLjE3MTk0ODM4OTY.*_ga_97ZFJSQQ0X*MTcxOTQ4Mzg5NS4xLjEuMTcxOTQ4NDQxNS4wLjAuMA
Amin MB, Smith SC, Reuter VE, Epstein JI, Grignon DJ, Hansel DE, et al. Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer. Mod Pathol. 2015;28(5):612-30. doi: https://doi.org/10.1038/modpathol.2014.158
Hansel DE, Amin MB, Comperat E, Cote RJ, Knüchel R, Montironi R, et al. A contemporary update on pathology standards for bladder cancer: transurethral resection and radical cystectomy specimens. Eur Urol. 2013;63(2):321-32. doi: https://doi.org/10.1016/j.eururo.2012.10.008
Chandra A, Griffiths D, McWilliam LJ. Best practice: gross examination and sampling of surgical specimens from the urinary bladder. J Clin Pathol. 2010;63(6):475-9. doi: https://doi.org/10.1136/jcp.2009.071191
Lopez-Beltran A, Luque RJ, Mazzucchelli R, Scarpelli M, Montironi R. Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer. J Clin Pathol. 2002;55(9):641-7. doi: https://doi.org/10.1136/jcp.55.9.641
Oxley JD, Cottrell AM, Adams S, Gillatt D. Ketamine cystitis as a mimic of carcinoma in situ. Histopathology. 2009;55(6):705-8. doi: https://doi.org/10.1111/j.1365-2559.2009.03437.x
Manini C, Angulo JC, López JI. Mimickers of Urothelial Carcinoma and the Approach to Differential Diagnosis. Clin Pract. 2021;11(1):110-23. doi: https://doi.org/10.3390/clinpract11010017
Chan TY, Epstein JI. Radiation or chemotherapy cystitis with "pseudocarcinomatous" features. Am J Surg Pathol. 2004;28(7):909-13. doi: https://doi.org/10.1097/00000478-200407000-00010
Teoh JY, MacLennan S, Chan VW, Miki J, Lee HY, Chiong E, et al. An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting. Eur Urol. 2020;78(4):546-69. doi: https://doi.org/10.1016/j.eururo.2020.04.059
Brausi M, Collette L, Kurth K, van der Meijden AP, Oosterlinck W, Witjes JA, et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41(5):523-31. doi: https://doi.org/https://doi.org/10.1016/s0302-2838(02)00068-4
Teoh JY, Mayor N, Li KM, Lo KL, Ng CF, Mostafid H. En-bloc resection of bladder tumour as primary treatment for patients with non-muscle-invasive bladder cancer: routine implementation in a multi-centre setting. World J Urol. 2021;39(9):3353-8. doi: https://doi.org/10.1007/s00345-021-03675-9
Richterstetter M, Wullich B, Amann K, Haeberle L, Engehausen DG, Goebell PJ, et al. The value of extended transurethral resection of bladder tumour (TURBT) in the treatment of bladder cancer. BJU Int. 2012;110(2 Pt 2):E76-9. doi: https://doi.org/10.1111/j.1464-410X.2011.10904.x
D'Andrea D, Soria F, Hurle R, Enikeev D, Kotov S, Régnier S, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. Eur Urol Oncol. 2023;6(5):508-15. doi: https://doi.org/10.1016/j.euo.2023.07.010
Holzbeierlein J, Bixler BR, Buckley DI, Chang SS, Holmes RS, James AC, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). J Urol. 2024;212(1):3-10. doi: https://doi.org/10.1097/JU.0000000000003981
Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder Cancer: A Review. JAMA. 2020;324(19):1980-91. doi: https://doi.org/10.1001/jama.2020.17598
Paner GP, Kamat A, Netto GJ, Samaratunga H, Varma M, Bubendorf L, et al. International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 2: Grading of Mixed Grade, Invasive Urothelial Carcinoma Including Histologic Subtypes and Divergent Differentiations, and Non-Urothelial Carcinomas. Am J Surg Pathol. 2024 Jan 1;48(1):e11-e23. doi: https://doi.org/10.1097/PAS.0000000000002077
Veskimäe E, Espinos EL, Bruins HM, Yuan Y, Sylvester R, Kamat AM, et al. What Is the Prognostic and Clinical Importance of Urothelial and Nonurothelial Histological Variants of Bladder Cancer in Predicting Oncological Outcomes in Patients with Muscle-invasive and Metastatic Bladder Cancer? A European Association of Urology Muscle Invasive and Metastatic Bladder Cancer Guidelines Panel Systematic Review. Eur Urol Oncol. 2019;2(6):625-42. doi: https://doi.org/10.1016/j.euo.2019.09.003
Wasco MJ, Daignault S, Zhang Y, Kunju LP, Kinnaman M, Braun T, et al. Urothelial carcinoma with divergent histologic differentiation (mixed histologic features) predicts the presence of locally advanced bladder cancer when detected at transurethral resection. Urology. 2007;70(1):69-74. doi: https://doi.org/10.1016/j.urology.2007.03.033
Linder BJ, Boorjian SA, Cheville JC, Sukov WR, Thapa P, Tarrell RF, et al. The impact of histological reclassification during pathology re-review--evidence of a Will Rogers effect in bladder cancer? J Urol. 2013;190(5):1692-6. doi: https://doi.org/10.1016/j.juro.2013.05.040
Gaisa NT, Braunschweig T, Reimer N, Bornemann J, Eltze E, Siegert S, et al. Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer. Virchows Arch. 2011;458(3):301-12. doi: https://doi.org/10.1007/s00428-010-1017-2
Zhao G, Wang C, Tang Y, Liu X, Liu Z, Li G, et al. Glandular differentiation in pT1 urothelial carcinoma of bladder predicts poor prognosis. Sci Rep. 2019;9(1):5323. doi: https://doi.org/10.1038/s41598-019-41844-4
Kim SP, Frank I, Cheville JC, Thompson RH, Weight CJ, Thapa P, et al. The impact of squamous and glandular differentiation on survival after radical cystectomy for urothelial carcinoma. J Urol. 2012;188(2):405-9. doi: https://doi.org/10.1016/j.juro.2012.04.020
Przybycin CG, McKenney JK, Nguyen JK, Shah RB, Umar SA, Harik L, et al. Urothelial Carcinomas With Trophoblastic Differentiation, Including Choriocarcinoma: Clinicopathologic Series of 16 Cases. Am J Surg Pathol. 2020;44(10):1322-30. doi: https://doi.org/10.1097/PAS.0000000000001532
Lopez-Beltran A, Henriques V, Montironi R, Cimadamore A, Raspollini MR, Cheng L. Variants and new entities of bladder cancer. Histopathology. 2019;74(1):77-96. doi: https://doi.org/10.1111/his.13752
Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol. 2009;22 Suppl 2:S96-S118. doi: https://doi.org/10.1038/modpathol.2009.26
Weyerer V, Eckstein M, Compérat E, Juette H, Gaisa NT, Allory Y, et al. Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype. Cancers (Basel). 2020;12(3):763. doi: https://doi.org/10.3390/cancers12030763
Compérat E, Roupret M, Yaxley J, Reynolds J, Varinot J, Ouzaïd I, et al. Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases. Pathology. 2010;42(7):650-4. doi: https://doi.org/10.3109/00313025.2010.522173
Meeks JJ, Taylor JM, Matsushita K, Herr HW, Donat SM, Bochner BH, et al. Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer. BJU Int. 2013;111(8):E325-30. doi: https://doi.org/10.1111/j.1464-410X.2012.11751.x
Sui W, Matulay JT, James MB, Onyeji IC, Theofanides MC, RoyChoudhury A, et al. Micropapillary Bladder Cancer: Insights from the National Cancer Database. Bladder Cancer. 2016 Oct 27;2(4):415-423. doi: https://doi.org/10.3233/BLC-160066
Ching CB, Amin MB, Tubbs RR, Elson P, Platt E, Dreicer R, et al. HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization. Mod Pathol. 2011;24(8):1111-9. doi: https://doi.org/10.1038/modpathol.2011.69
Guo CC, Dadhania V, Zhang L, Majewski T, Bondaruk J, Sykulski M, et al. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. Eur Urol. 2016;70(4):611-20. doi: https://doi.org/10.1016/j.eururo.2016.02.056
Al-Ahmadie HA, Iyer G, Lee BH, Scott SN, Mehra R, Bagrodia A, et al. Frequent somatic CDH1 loss-of-function mutations in plasmacytoid variant bladder cancer. Nat Genet. 2016;48(4):356-8. doi: https://doi.org/10.1038/ng.3503
Dayyani F, Czerniak BA, Sircar K, Munsell MF, Millikan RE, Dinney CP, et al. Plasmacytoid urothelial carcinoma, a chemosensitive cancer with poor prognosis, and peritoneal carcinomatosis. J Urol. 2013;189(5):1656-61. doi: https://doi.org/10.1016/j.juro.2012.11.084
Li Q, Assel M, Benfante NE, Pietzak EJ, Herr HW, Donat M, et al. The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy. Eur Urol Focus. 2019;5(1):104-8. doi: https://doi.org/10.1016/j.euf.2017.06.013
Compérat E, Oszwald A, Wasinger G, Hansel DE, Montironi R, van der Kwast T, et al. Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies. World J Urol. 2022;40(4):915-27. doi: https://doi.org/10.1007/s00345-021-03831-1
Yang G, Bondaruk J, Cogdell D, Wang Z, Lee S, Lee JG, et al. Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. iScience. 2020;23(6):101201. doi: https://doi.org/10.1016/j.isci.2020.101201
Guo CC, Majewski T, Zhang L, Yao H, Bondaruk J, Wang Y, et al. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep. 2019;27(6):1781-1793.e4. doi: https://doi.org/10.1016/j.celrep.2019.04.048
Meeks JJ, Al-Ahmadie H, Faltas BM, Taylor JA 3rd, Flaig TW, DeGraff DJ, et al. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nat Rev Urol. 2020;17(5):259-70. doi: https://doi.org/10.1038/s41585-020-0304-1
Compérat E, Amin MB, Epstein JI, Hansel DE, Paner G, Al-Ahmadie H, et al. The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers. Adv Anat Pathol. 2021;28(4):196-208. doi: https://doi.org/10.1097/PAP.0000000000000309
Paner GP, Montironi R, Amin MB. Challenges in Pathologic Staging of Bladder Cancer: Proposals for Fresh Approaches of Assessing Pathologic Stage in Light of Recent Studies and Observations Pertaining to Bladder Histoanatomic Variances. Adv Anat Pathol. 2017;24(3):113-27. doi: https://doi.org/10.1097/PAP.0000000000000152
Amin MB, Edge S, Greene FL, Schilsky RL, Byrd DR, Gaspar LE, et al., editors. AJCC Cancer Staging Manual. 8th ed. Cham, Switzerland: Springer International Publishing; 2016.
Lemos MB, Okoye E. Atlas of Surgical Pathology grossing. Cham: Springer; 2019.
Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol. 2013;64(4):639-53. doi: https://doi.org/10.1016/j.eururo.2013.06.003
Lopez-Beltran A, Bassi PF, Pavone-Macaluso M, Montironi R; European Society of Uropathology; Uropathology Working Group. Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis. A joint proposal of the European Society of Uropathology and the Uropathology Working Group. Virchows Arch. 2004;445(2):103-10. doi: https://doi.org/10.1007/s00428-004-1039-8
Mariappan P, Finney SM, Head E, Somani BK, Zachou A, Smith G, et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int. 2012;109(11):1666-73. doi: https://doi.org/10.1111/j.1464-410X.2011.10571.x
Mariappan P, Finney SM, Head E, Somani BK, Zachou A, Smith G, et al. Good quality white-light transurethral resection of bladder tumours (GQ-WLTURBT) with experienced surgeons performing complete resections and obtaining detrusor muscle reduces early recurrence in new non-muscle-invasive bladder cancer: validation across time and place and recommendation for benchmarking. BJU Int. 2012;109(11):1666-73. doi: https://doi.org/10.1111/j.1464-410X.2011.10571.x
Werntz RP, Smith ZL, Packiam VT, Smith N, Steinberg GD. The Impact of Lymphovascular Invasion on Risk of Upstaging and Lymph Node Metastasis at the Time of Radical Cystectomy. Eur Urol Focus. 2020;6(2):292-7. doi: https://doi.org/10.1016/j.euf.2018.09.019
Mari A, Kimura S, Foerster B, Abufaraj M, D'Andrea D, Gust KM, et al. A systematic review and meta-analysis of lymphovascular invasion in patients treated with radical cystectomy for bladder cancer. Urol Oncol. 2018;36(6):293-305. doi: https://doi.org/10.1016/j.urolonc.2018.03.018
Lotan Y, Gupta A, Shariat SF, Palapattu GS, Vazina A, Karakiewicz PI, et al. Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol. 2005;23(27):6533-9. doi: https://doi.org/10.1200/JCO.2005.05.516
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeThe Effect of Open Access).
